UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 16, 2014
Yew Bio-Pharm Group, Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 000-54701 | 26-1579105 | ||
|
(State or other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
723 South Casino Center Blvd. Las Vegas, Nevada |
89101 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (702) 487-4683
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Information included in this Form 8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Yew Bio-Pharm Group, Inc. (herein referred to as the “Company” or “Registrant”), to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. The Company’s actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.
Section 7- Regulation FD
Item 7.01 Regulation FD Disclosure
On December 16, 2014, the Company issued a press release announcing that it is entering into the U.S. health supplement market, through a collaboration with an American health supplement company to research and develop agaric polysaccharide (black fungus extract) and its related health supplements, which will be produced in the U.S. and sold to both American and Chinese markets
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This disclosure does not constitute an offer to sell, or the solicitation to buy, any such security.
| Item 9.01 | Financial Statements and Exhibits. |
|
Exhibit Number |
Description | |
| 99.1 | Press release, dated December 16, 2014 of Yew Bio-Pharm Group, Inc. |
Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.
| Yew Bio-Pharm Group, Inc. | ||
| Date: December 17, 2014 | By: | /s/ Zhiguo Wang |
| Zhiguo Wang | ||
| President & Chief Executive Officer | ||
Exhibit 99.1
Yew Bio-Pharm to Enter U.S. Health Supplement Market
With Two New Agaric Polysaccharide Products Focused on Enhancing Immunity
HARBIN, CHINA, December 16, 2014 -- Yew Bio-Pharm Group, Inc. (“Yew Bio” or the “Company”) (OTCBB: YEWB), today announced that it is entering into the U.S. health supplement market, through a collaboration with an American health supplement company to research and develop agaric polysaccharide (black fungus extract) and its related health supplements, which will be produced in the U.S. and sold to both American and Chinese markets. The new products are expected to launch in the first half of 2015.
Black fungus is known to benefit health issues associated with the lungs, stomach and liver in the Eastern culture. It is rich in iron, protein, vitamins, polysaccharide, fiber, and other minerals, which often are used in Chinese cooking and traditional Chinese medicine.
Yew Bio plans to initially launch two agaric polysaccharide products, which include a beverage powder and capsule, with tastes specifically designed for both the American and Chinese markets. The Company also intends to continue new product introductions through the second half of 2015 and into 2016. Yew Bio said the new health supplements enable body functions to absorb microelements and bio-activators and make full use of the nutrition and medicinal value from black fungus.
According to the Chinese Health Food Industry Monitoring and Marketing Research Report, the agaric polysaccharide extracted from black fungus could promote cellular and humoral immunity. Additional functions include anti-leukopenia, anti-cancer, anti-radiation, anti-mutation, anti-inflammatory, lowering blood fat and cholesterol. The total worldwide sales of vitamins and dietary supplements were estimated to be $84.26 billion in 2011, with nearly 26% sold in the U.S. and 13% in China. Furthermore, according to a forecast from China's Healthcare Association, sales of vitamins and dietary supplements in China are estimated to increase up to 10% annually.
“Agaric polysaccharide has special properties that help balance certain human body functions,” said Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group. “We believe that introduction of our products in both powder and capsule forms hold much promise for our company in the growing health supplement market, both in the U.S. and China. We will continue to seize opportunities in other markets and to introduce additional products in the future.”
ABOUT YEW BIO-PHARM GROUP, INC.
Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. Yew Bio-Pharm also recently established a division to focus on organic foods and dietary supplements. To learn more, please visit http://www.yewbiopharm.com.
| Company Contacts: | Investor Relations Contacts: |
| Henry Pang | Cami Xue |
| Yew Bio-Pharm Group, Inc. | Chineseinvestors.com, Inc. |
| Tel: (702) 487-4683 | Tel: 800-958-8561 |
| hpang@yewbiopharm.com | cami@chinesefn.com |
# # #